ArticleAntimicrobial agents and chemotherapy2002
Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- MaAreB, a GATA Transcription Factor, Is Involved in Nitrogen Source Utilization, Stress Tolerances and Virulence inJournal of fungi (Basel, Switzerland) · 2021Article
- Assessment of the mechanism of drug resistance in Trichophyton mentagrophytes in response to various substances.BMC genomics · 2021Article
- Hyperexpression of CDRs and HWP1 genes negatively impacts on Candida albicans virulence.PloS one · 2021Article
- Increasing Susceptibility of Drug-ResistantMolecules (Basel, Switzerland) · 2020Article
- Fluconazole Resistance Candida albicans in Females With Recurrent Vaginitis and Pir1 Overexpression.Jundishapur journal of microbiology · 2015Article
- Candida albicans ENO1 null mutants exhibit altered drug susceptibility, hyphal formation, and virulence.Journal of microbiology (Seoul, Korea) · 2013Article
- The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida.Virulence · 2012Review
- A screening assay based on host-pathogen interaction models identifies a set of novel antifungal benzimidazole derivatives.Antimicrobial agents and chemotherapy · 2011Article
- Effect of Saccharomyces cerevisiae ret1-1 mutation on glycosylation and localization of the secretome.Molecules and cells · 2011Article
- Candida albicans virulence and drug-resistance requires the O-acyltransferase Gup1p.BMC microbiology · 2010Article
- Mutants of Candida albicans hypersensitive to calcofluor white display susceptibility to antifungal drugs.Folia microbiologica · 2010Article
- Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.Antimicrobial agents and chemotherapy · 2007Article
- Proteomic analysis of Candida albicans cell walls reveals covalently bound carbohydrate-active enzymes and adhesins.Eukaryotic cell · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of major glucan-associated proteins (GAPs) of the cell wall of a number of Candida albicans isolates susceptible or resistant to fluconazole (FLC) was addressed by direct sequencing of the protein bands resolved by unidimensional gel electrophoresis. Changes in the GAP compositions of the different strains grown in the presence of the drug were also investigated. In the FLC-susceptible strains, the major (more abundant) GAPs were enolase (46 kDa), two isoforms of phosphoglyceromutase (32 and 29 kDa), and two beta-(1-3)-exoglucanases (44 and 34 kDa), one of which (the 34-kDa component) was glycosylated. When these strains were grown in the presence of FLC there were substantial decreases in the intensities of the two enzymes of the glycolytic pathway (enolase and the phosphoglyceromutases), which were apparently replaced by enhancement of the exoglucanase constituents, particularly the 44-kDa one. This GAP pattern closely mimicked that observed in the FLC-resistant strains whether they were grown in the presence or in the absence of the drug. Both the enolase and the exoglucanase constituents were detected in the culture supernatants of FLC-treated cells, together with substantial amounts of highly glycosylated, probably mannoprotein secretory material, suggesting that FLC may cause marked alterations of GAP incorporation into the cell wall. Altogether, we were able to identify all major GAP constituents and monitor their distributions in the cell wall of C. albicans during treatment with FLC. The near equivalence of the GAP profile for the FLC-susceptible strain grown in the presence of FLC to that for the FLC-resistant strain suggests that the effects of the drug on GAPs may be stably incorporated into the cell wall of the fungus upon acquisition of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.